Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
  • C07D471/16—Peri-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

• This disclosure relates to certain salts and crystal forms of a substituted heterocycle fused gamma-carboline, the manufacture thereof, pharmaceutical compositions thereof, and use thereof, e.g., in the treatment of diseases or abnormal conditions involving or mediated by the 5-HT 2A receptor, serotonin transporter (SERT), and/or dopamine D I /D 2 receptor signaling pathways.
• SERT serotonin transporter
• ITI-007 is currently in clinical trials, e.g., for the treatment of schizophrenia, depression, and other psychological disorders. While ITI-007 is a promising drug, its production and formulation present challenges. In free base form, ITI-007 is an oily, sticky solid, with poor aqueous solubility. Making salts of the compound has proven to be unusually difficult.
• a hydrochloride salt form of ITI-007 was disclosed in U.S. Patent 7,183,282, but this particular salt form was hygroscopic and showed poor stability. It was obtained by precipitation from diethyl ether.
• a toluenesulfonic acid addition salt (tosylate) of ITI-007 was finally identified and described in WO 2009/114181 and US 2011/0112105 (U.S. Patent 8,648,077).
• ITI-007 does not readily form salts with other common, pharmaceutically acceptable acids, despite the good solubility of the free base in a variety of organic solvents.
• a toluenesulfonic acid addition salt tosylate
• WO 2009/114181 and US 2011/0112105 no other stable salts were found.
• a major salt screen was carried out, wherein the free base compound was studied in different solvent systems and under different conditions, and then systematically screened using a selection of over 100 acids under different conditions and with different solvent, co-solvent and anti-solvent systems, to identify new possible salt forms.
• a new bis-tosylate salt polymorph was discovered. This new bistosylate salt form is crystalline and stable.
• the present disclosure thus provides a new bis-tosylate salt form of ITI-007, which is especially advantageous for use in the preparation of galenic formulations, together with methods of making and using the same.
• This disclosure shows that this new bis-tosylate salt form of ITI- 007 can be prepared under various conditions, including from the free base form of ITI-007, as well as from the mono-tosylate salt form of ITI-007.
• Figure 1 depicts overlaid X-ray powder diffraction (XRPD) patterns for the ITI-007 bis- tosylate salt crystal obtained from Example 1 (from a 1 : 1 molar mixture of ITI-007 free base and toluenesulfonic acid) (upper curve), with reference to the known XRPD pattern for ITI-007 mono- tosylate salt crystal (lower curve).
• XRPD X-ray powder diffraction
• Figure 2 depicts the TGA-DSC thermogram of the ITI-007 bis-tosylate salt crystal obtained from Example 1.
• Figure 3 depicts the 1H-NMR spectrum of the ITI-007 bis-tosylate salt crystal obtained from Example 1.
• Figure 4 depicts the FTIR spectrum of the ITI-007 bis-tosylate salt crystal obtained from Example 1.
• Figure 5 depicts overlaid X-ray powder diffraction (XRPD) patterns for the ITI-007 mono- tosylate salt crystal obtained from Example 2 (from a 2: 1 molar mixture of ITI-007 free base and toluenesulfonic acid) (upper curve), with reference to the known XRPD pattern for ITI-007 mono- tosylate salt crystal (lower curve).
• XRPD X-ray powder diffraction
• Figure 6 depicts the TGA-DSC thermogram of the ITI-007 bis-tosylate salt crystal obtained from Example 2.
• Figure 7 depicts the 1H-NMR spectrum of the ITI-007 bis-tosylate salt crystal obtained from Example 2.
• the invention provides l-(4-fluorophenyl)-4-((6bR,l0aS)-3 -methyl- 2, 3, 6b, 9,10, l0a-hexahydro-lH,7H-pyrido[3 ',4':4, 5]pyrrolo[l, 2, 3-de]quinoxalin-8-yl)-butan-l- one (ITI-007) in stable bis-tosylate salt form (Salt 1).
• the invention further provides the following:
• Salt 1 wherein the salt is in solid form.
• Salt 1 or 1.1 wherein the salt is in crystalline form, e.g., dry crystalline form.
• Salt 1.2 wherein the salt is in a homogeneous crystal form, e.g., free or substantially free of other forms of ITI-007, e.g., free or substantially free, e.g., less than 10 wt. %, preferably less than about 5 wt. %, more preferably less than about 2 wt. %, still preferably less than about 1 wt. %, still preferably less than about 0.1 %, most preferably less than about 0.01 wt. %, of any amorphous forms.
• a homogeneous crystal form e.g., free or substantially free of other forms of ITI-007, e.g., free or substantially free, e.g., less than 10 wt. %, preferably less than about 5 wt. %, more preferably less than about 2 wt. %, still preferably less than about 1 wt. %, still preferably less than about 0.1 %, most preferably less than
• Salt 1 Any foregoing form of Salt 1, wherein the salt is a solvate, e.g., a 2-butanone solvate.
• Salt 1 any foregoing form of Salt 1, wherein the salt is formed by combining free ITI-007 free base and toluenesulfonic acid in a molar ratio from 1 : 1 to 1 :3, e.g., a molar ratio from 1 : 1 to 1 :2.2, or from 1 : 1 to 1 :2, or from 1 :1 to 1 : 1.5, or a molar ratio of about 1 : 1, or about 1 : 1.5, or about 1 :2, or about 1 :2.2.
• Salt 1 Any foregoing form of Salt 1, wherein the salt is formed from a slurry of ITI-007 free base and toluenesulfonic acid in 2-butanone solvent.
• Salt 1 any foregoing form of Salt 1 , wherein the salt is in the form of a crystal having an X-ray powder diffraction pattern corresponding to Figure 1 (upper curve), e.g., taking into account potential variations due to sample purity and instrument variation, for example 2Q shifts due to variation in X-ray wavelength, e.g., an X-ray powder diffraction pattern corresponding to Figure 1 generated using an X-ray diffractometer with a copper anode and a nickel filter.
• an X-ray powder diffraction pattern corresponding to Figure 1 generated using an X-ray diffractometer with a copper anode and a nickel filter.
• any foregoing form of Salt 1 in the form of a crystal having an X-ray powder diffraction pattern having at least 5, or at least 6, or at least 7, or at least 8, peaks having d-spacing values selected from the group consisting of about 13.91, 10.53, 8.46, 6.42, 6.21, 6.04, 5.93, 5.75, 5.56, 5.37, 5.18, 4.95, 4.75, 4.62, 4.33, 4.29, 4.26, 3.95, 3.88, 3.71, 3.54, 3.44, 3.30, 3.25, 3.10, 3.06, 2.96, 2.83, 2.68, 2.53, 2.46, 2.27, 2.12, and 2.07, taking into account potential variations due to sample purity and instrument variation, wherein the X-ray powder diffraction pattern is generated using an X-ray diffractometer with a copper anode and a nickel filter.
• any foregoing form of Salt wherein the salt is in the form of a crystal having an X-ray powder diffraction pattern having at least a peak of 25% relative intensity at an angle (2-theta) value of 10.2-10.5 (e.g., 10.3-10.5, or about 10.3, or about 10.4 or about 10.45, or about 10.5), optionally, wherein said peak has a relative intensity of at least 30% or at least 40% or at least 50%, or about 25% or about 30%, or about 35%.
• any foregoing form of Salt 1 wherein the salt is in the form of a crystal having an X-ray powder diffraction powder having relative angle (2 -theta) values as provided in the table of embodiment 1.12, wherein the values are shifted by up to +/- 0.2 degrees, e.g., wherein the values are substantially uniformly shifted by up to +/- 0.2 degrees.
• any foregoing form of Salt 1 wherein the salt contains less than 10 wt% of any other ITI-007 tosylate salt form (e.g., mono-tosylate salt or tri-tosylate salt), e.g., less than 5%, or less than 3%, or less than 2%, or less than 1%, or less than 0.5%, by weight of Salt 1 1.25.
• any foregoing form of Salt 1 wherein the ITI-007 is deuterated, e.g., wherein the deuterium :protium ratio at one or more specified positions in the molecule is significantly higher, e.g., at least 2x, for example at least lOx higher, than the natural isotope ratios or the isotope ratios at other positions in the molecule; for example, any foregoing form of Salt 1 wherein the -CH 2- adjacent to the methylated nitrogen moiety and/or adjacent to the carbonyl moiety of ITI-007 is deuterated, e.g., is in the form of -CHD- or -CD 2- at levels which are significantly higher than the natural deuterium :protium isotope ratio or the deuterium :protium isotope ratio at other positions in the molecule, and/or wherein the methyl group is deuterated, e.g., is CD 3- , e.g., at levels which are significantly higher than
• the invention provides a process (Process 1) for the production of Salt 1, comprising
• reaction step (a) comprises dissolving or suspending the ITI-007 free base in an organic solvent, e.g., 2-butanone, and adding thereto the toluenesulfonic acid.
• reaction step (a) comprises combining the ITI-007 free base with the toluenesulfonic acid and adding thereto an organic solvent, e.g., 2-butanone.
• the process step (a) is carried out as a batch process, and in other embodiments the process step (a) is carried out as a continuous (flow) process.
• the invention provides a pharmaceutical composition
• a pharmaceutical composition comprising Salt 1, or any of Salts 1.1-1.27, as active ingredient, in combination or association with a pharmaceutically acceptable diluent or carrier.
• the invention provides a pharmaceutical composition
• a pharmaceutical composition comprising Salt 1, or any of Salts 1.1-1.27, as active ingredient, in combination or association with a pharmaceutically acceptable diluent or carrier, wherein the salt is predominantly, or is entirely or substantially entirely, in dry crystalline form.
• the invention provides a pharmaceutical composition
• a pharmaceutical composition comprising Salt 1, or any of Salts 1.1-1.27, as active ingredient, in combination or association with a pharmaceutically acceptable diluent or carrier, wherein the composition is in the form of an injectable depot, e.g., to provide extended release of ITI-007.
• composition 2 comprising:
• the acid addition salt of ITI-007 in part (l)(b) is a hydrochloride salt of ITI-007.
• the invention provides a method of making Composition 2 comprising the steps of:
• the invention provides Salt 1, or any of Salts 1.1-1.27, or a pharmaceutical composition comprising Salt 1, or any of Salts 1.1-1.27, for use in treating a disease or abnormal condition involving or mediated by the 5-HT 2 A receptor, serotonin transporter (SERT), and/or dopamine D I /D 2 receptor signaling pathways, e.g., a disorder selected from obesity, anorexia, bulimia, depression, anxiety, psychosis, schizophrenia, migraine, obsessive- compulsive disorder, sexual disorders, bipolar depression, attention deficit disorder, attention deficit hyperactivity disorder, sleep disorders, conditions associated with cephalic pain, social phobias, and/or dementia.
• a disorder selected from obesity, anorexia, bulimia, depression, anxiety, psychosis, schizophrenia, migraine, obsessive- compulsive disorder, sexual disorders, bipolar depression, attention deficit disorder, attention deficit hyperactivity disorder, sleep disorders, conditions associated with cephalic pain, social phobias, and/or dementia e.
• the invention provides a method for the prophylaxis or treatment of a human suffering from a disease or abnormal condition involving or mediated by the 5-HT 2 A receptor, serotonin transporter (SERT), and/or dopamine D I /D 2 receptor signaling pathways, e.g., a disorder selected from obesity, anorexia, bulimia, depression, anxiety, psychosis, schizophrenia, migraine, obsessive-compulsive disorder, sexual disorders, bipolar depression, attention deficit disorder, attention deficit hyperactivity disorder, sleep disorders, conditions associated with cephalic pain, social phobias, and/or dementia, the method comprising administering to a patient in need thereof a therapeutically effective amount of Salt 1, or any of Salts 1.1-1.27.
• the standard sample holder (0.1 mm cavity in (510) silicon wafer) has a minimal contribution to the background signal. Measurement conditions: scan range 5 - 45° 2Q, sample rotation 5 rpm, 0.5s/step, 0.0l0°/step, 3.0mm detector slit; and all measuring conditions are logged in the instrument control file. As system suitability, corundum sample A26- B26-S (NIST standard) is measured daily.
• the software used for data collection is Diffrac. Commander v2.0.26. Data analysis is done using Diffrac.Eva vl .4. No background correction or smoothing is applied to the patterns.
• TGA thermogravimetry
• DSC differential scanning calorimetry
• TGA/DSC studies are performed using a Mettler Toledo TGA/DSC1 Stare System, equipment #1547, auto-sampler equipped, using pin-holed Al- crucibles of 40 m ⁇ . Measurement conditions: 5 min 30.0 °C, 30.0 - 350.0 °C with 10 °C/min., N 2 flow of 40 ml/min.
• the software used for instrument control and data analysis is STARe vl2.10.
• DSC Differential scanning calorimetry
• FT-IR Fourier transform infrared spectroscopy
• High performance liquid chromatography HPLC: The high performance liquid chromatography analyses are performed on an LC-31, equipped with an Agilent 1100 series G1322A degasser equipment #1894, an Agilent 1100 series G1311 A quaternary pump equipment #1895, an Agilent 1100 series G1313A ALS equipment #1896, an Agilent 1100 series G1318A column equipment #1897 and an Agilent 1100 series G1314A VWD equipment #1898 / LC-34, equipped with an Agilent 1200 series G1379B degasser equipment #2254, an Agilent 1100 series G1311A quaternary pump equipment #2255, Agilent 1100 series G1367A WPALS equipment #1656, an Agilent 1100 series G1316A column equipment #2257 and an Agilent 1100 series G1315B DAD equipment #2258.
• HPLC High performance liquid chromatography
• XRPD analysis shows the obtained solid to be a crystalline solid.
• the XRPD pattern is shown in Figure 1 (upper curve) with reference to the XRPD pattern obtained from a previously made ITI-007 mono-tosylate salt crystal (lower curve).
• the reference crystal was obtained from a 1 : 1 molar mixture of ITI-007 and toluenesulfonic acid using ethyl acetate or toluene as solvent.
• the results show clear differences in the XPRD pattern between the solid obtained by Example 1 and the reference ITI-007 mono-tosylate salt.
• One key distinguishing peak that is believed to signal formation of the bis-tosylate salt appears at an angle (2 -theta) of about 10.45.
• the peaks for the compound of Example 1 are identified in tabular form in table 1 :
• the DSC/TGA thermogram is shown in Figure 2.
• DSC/TGA analysis shows one endothermic event at about l84°C, and one exothermic event at about 258 °C.
• the endothermic event is a melt, while the exothermic event is a recrystallization.
• the TGA profile shows a mass loss of 1.7% from 40 °C to 190 °C, and a mass loss of 3.4% from 210 °C to 270 °C. It is noted that the recrystallization event occurs at a temperature about 25 °C lower than that previously observed for the reference ITI-007 mono-tosylate salt crystal. [0040] LC-MS analysis shows a purity of 92 area% for the obtained solid.
• Proton NMR is shown in Figure 3.
• Proton NMR analysis shows that the compound is the bis-tosylate salt of ITI-007.
• the proton NMR spectrum shows the presence of about two toluenesulfonic acid moieties per ITI-007 base moiety. This is demonstrated by the NMR protons at about 7.11 ppm, 7.36 ppm, 7.49 ppm and 8.03 ppm, which are present at an integral ratio of about 4:2:4:2.
• the 7.11 and 7.49 ppm peaks represent protons from the aromatic tosylate ring of the toluene sulfonate moiety, while the 7.36 and 8.03 peaks represent protons from the aromatic 4-fluorophenyl ring of the ITI-007 moiety.
• the remaining aromatic peaks between 6.4 and 7.0 ppm represent the aromatic protons of the quinoxaline core of ITI-007 and their integral is consistent with one molar unit of ITI-007 free base.
• the alkyl peak at about 2.3 ppm represents the methyl group of the tosylate rings and its integral is also consistent with two molar units of toluenesulfonic acid.
• Dynamic vapor sorption (DVS) analysis shows a stepwise sorption with a total mass uptake at 95 RH% of 2%. This salt is thus slightly hygroscopic. Analysis results are summarized in Table 2 below.
• Example 2 it is apparent that the salt of Example 1 is a distinct crystalline salt form comprising a 1 :2 molar ratio of ITI-007 free base to toluene sulfonic acid.
• the lower solubility of ITI-007 free base in 2-butanone solvent compared to other solvents, result in the effective concentration of free base being lower, and the effective ratio of free base to toluenesulfonic acid being higher.
• the bis-tosylate salt forms and unreacted free base remains in solution after filtration of the product.
• XRPD analysis shows the obtained solid to be a crystalline solid.
• the XRPD pattern is shown in Figure 5 (upper curve) with reference to the XRPD pattern obtained from a previously made ITI-007 mono-tosylate salt crystal (lower curve).
• the reference crystal was obtained from a 1 : 1 molar mixture of ITI-007 and toluenesulfonic acid using ethyl acetate or toluene as solvent.
• the results show substantially the same XPRD pattern between the solid obtained by Example 2 and the reference ITI-007 mono-tosylate salt.
• the peaks for the compound of Example 2 are identified in tabular form in table 3 :
• the DSC/TGA thermogram is shown in Figure 6.
• DSC/TGA analysis shows one endothermic event at about 179 °C, and one exothermic event at about 285 °C.
• the endothermic event is a melt, while the exothermic event is a recrystallization.
• the TGA profile shows a mass loss of 0.4% from 40 °C to 220 °C, and a mass loss of 9.4% from 220 °C to 290 °C.
• Proton NMR is shown in Figure 7.
• Proton NMR analysis shows that the compound is the mono-tosylate salt of ITI-007.
• the spectrum proton NMR spectrum shows the presence of one toluenesulfonic acid moiety per ITI-007 base moiety. This is demonstrated by the NMR protons at about 7.11 ppm, 7.36 ppm, 7.52 ppm and 8.05 ppm, which are present at an integral ratio of about 2:2:2:2.
• the 7.11 and 7.52 ppm peaks represent protons from the aromatic tosylate ring, while the 7.36 and 8.05 peaks represent protons from the aromatic 4-fluorophenyl ring of the ITI-007 free base.
• the remaining aromatic peaks between 6.4 and 7.0 ppm represent the aromatic protons of the quinoxaline core of ITI-007 and their integral is consistent with one molar unit of ITI-007 free base (integrals in a 1 : 1 : 1 ratio of clearly distinct peaks).
• the alkyl peak at about 2.3 ppm represents the methyl group of the tosylate ring and its integral is also consistent with one molar unit of toluenesulfonic acid.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Neurology (AREA)
• Psychiatry (AREA)
• Biomedical Technology (AREA)
• Neurosurgery (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pain & Pain Management (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=68769581

Family Applications (1)

Country Status (11)

Cited By (5)

Families Citing this family (11)

Citations (7)

Family Cites Families (70)

• 2019
  • 2019-06-06 IL IL321985A patent/IL321985A/en unknown
  • 2019-06-06 CN CN201980045584.5A patent/CN112384218B/zh active Active
  • 2019-06-06 KR KR1020217000311A patent/KR102888393B1/ko active Active
  • 2019-06-06 EP EP19815334.8A patent/EP3628007B1/en active Active
  • 2019-06-06 CA CA3102848A patent/CA3102848A1/en active Pending
  • 2019-06-06 IL IL279195A patent/IL279195B2/en unknown
  • 2019-06-06 BR BR112020024885-1A patent/BR112020024885A2/pt unknown
  • 2019-06-06 WO PCT/US2019/035845 patent/WO2019236889A1/en not_active Ceased
  • 2019-06-06 AU AU2019280850A patent/AU2019280850C1/en active Active
  • 2019-06-06 JP JP2020567784A patent/JP7476115B2/ja active Active
  • 2019-06-06 MX MX2020013116A patent/MX2020013116A/es unknown
  • 2019-12-13 US US16/714,139 patent/US20200157100A1/en not_active Abandoned
• 2022
  • 2022-02-22 US US17/652,076 patent/US12195464B2/en active Active

Patent Citations (11)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events